About US
Contact us
-
With patent strikedown, Teva's new Copaxone formula loses two defenses against genericsBad news for Teva, much-needed good news for the embattled Mylan: The U.S. Patent and Trademark office’s review board struck down two patents on Teva’s new long-acting multiple sclerosis med Copaxone.2016/9/19
-
Novartis bankers assembling big investors for $14B Roche stake sale: HandelszeitungNovartis ($NVS) is getting closer to unloading its $14 billion stake in crosstown rival Roche ($RHHBY). According to areportthis week in the Zurich newspaperHandelszeitung, big investors have been sho2016/9/14
-
Pfizer grabs AZ antibiotics in $1.5B deal. Pre-split prep or just another sales-boosting buy?It’s been a busy week for Pfizer. Fresh off its $14 billion deal for Medivation, the drug giant is snapping up a portfolio of AstraZeneca antibiotics for up to $1.5 billion--a portfolio that just happ2016/9/14
-
Investors bid up post-Medivation M&A targets BioMarin, Incyte and moreWhen one M&A door closes, many potential windows open. At least that was the operative theory Mondayafter Pfizer ($PFE) said it had wrapped up a $14 billion deal for Medivation ($MDVN), leaving a2016/9/13
-
Pfizer plans to shell out a stunning $14B for Medivation. Will the bet pay off?The Medivation hunt is over. Pfizer has struck a deal to buy the California-based biotech for a whopping $14 billion. The next question is this: Will the buy deliver much payoff for the drug giant? O2016/9/13
-
NICE backs Pfizer's Xalkori after squeezing out a new discountWhile many of itspeers have publicly attacked England’s price watchdog NICE in recent weeks, Pfizer ($PFE) is on a bit of a hot streak. In itssecond recommendationin as many months, the company won ba2016/9/12
-
Merck joins Pfizer, Sanofi in high-stakes hunt for MedivationMerck & Co. wants Medivation, too. Not content to let another Big Pharma snap up the cancer-focused biotech unchallenged, Merck has joined the fight for a prize valued at more than $10 billion. R2016/9/12
-
M&As this week: Allergan, Asahi GlassPharmaceutical companyAllerganhas acquired all assets of biotechnology company RetroSense Therapeutics through an all-cash transaction worth $60m. "The acquisition enables Allergan to further advance2016/9/9
-
Report: Philippines pharmaceutical market to grow at CAGR of 3.7% to reach $4.1bn by 2020The Philippines pharmaceutical market is projected to rise moderately from $3.4bn in 2015 to $4.1bn by 2020 at a compound annual growth rate of 3.7%, according to a new report by GlobalData. Titled '2016/9/9
-
New research discovers compounds with potential to prevent transmission of malariaResearchers at the Broad Institute of MIT and Harvard have discovered compounds with potential to prevent thetransmission of malaria. The new compounds act on a novel target in the malaria parasite,2016/9/8